Patients with various solid tumors develop antibodies against the growth suppressor protein p53. The percentage of positive sera for patients with colon cancer varied over a wide range, which might be due to the different methods or the different antigens, which were used for the detection of p53 autoantibodies. We analyzed sera from patients with diagnosed colon cancer by ELISA using native p53 from a tumor cell line as well as by Western blotting with full-length or C- or N-terminal fragments of p53. Finally, sera were analyzed with a peptide library consisting of 16-amino-acid peptides, which cover the entire p53 sequence. By using these different methods we found 7 out of 127 sera (5.5%) to be positive for p53 autoantibodies. Two antibodies out of 7 reacted only with epitopes in the N-terminus whereas 5 sera reacted with N- and C-terminal sequences. All of these sera recognized common epitopes, which are also detected by a number of mouse monoclonal antibodies indicating immune-dominant epitopes for mouse and man on the polypeptide chain of p53. The sequences of these epitopes might be useful for the treatment of tumor patients either by neutralizing p53 autoantibodies or for vaccination.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Diagnostic value of multi-tumor-associated autoantibody expression in esophageal squamous cell carcinoma and correlation of clinical features.
Front Immunol
January 2025
Zhongshan City People's Hospital, Zhongshan, Guangdong, China.
Objective: This study aimed to investigate the diagnostic value of 7-tumor associated autoantibodies (7-TAAB) and to evaluate the relationship between 7-TAAB and clinical features in esophageal squamous cell carcinoma (ESCC), which can be used to guide clinical diagnosis and treatment and achieve its clinical value.
Methods: (1) Blood specimens were collected from patients with ESCC who had not previously received antitumor therapy (ESCC group) and those who had normal medical check-ups in the hospital during the same period (control group). The concentrations of 7-TAAB (P53, PGP9.
The diagnostic efficacy of seven autoantibodies in early detection of ground-glass nodular lung adenocarcinoma.
Front Oncol
November 2024
Department of Pulmonary and Critical Care Medicine, Chinese People's Liberation Army General Hospital, Beijing, China.
Background: Persistent ground-glass nodules (GGNs) carry a potential risk of malignancy, however, early diagnosis remained challenging. This study aimed to investigate the cut-off values of seven autoantibodies in patients with ground-glass nodules smaller than 3cm, and to construct machine learning models to assess the diagnostic value of these autoantibodies.
Methods: In this multi-center retrospective study, we collected peripheral blood specimens from a total of 698 patients.
Assessing the 9G Technology Blood Test for Predicting Lung Cancer in Patients with CT-Detected Lung Nodules: A Multicenter Clinical Trial.
Cancers (Basel)
November 2024
Precision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul 05029, Republic of Korea.
: Lung nodules detected by chest computed tomography (CT) often require invasive biopsies for definitive diagnosis, leading to unnecessary procedures for benign lesions. A blood-based biomarker test that predicts lung cancer risk in CT-detected nodules could help stratify patients and direct invasive diagnostics toward high-risk individuals. : In this multicenter, single-blinded clinical trial, we evaluated a test measuring plasma levels of p53, anti-p53 autoantibodies, CYFRA 21-1, and anti-CYFRA 21-1 autoantibodies in patients with CT-detected lung nodules.
View Article and Find Full Text PDFThe clinical value of combined detection of seven lung cancer-related autoantibodies in assisting the diagnosis of non-small-cell lung cancer.
Biomark Med
October 2024
The First People's Hospital of Fuyang District, Laboratory Department, Hangzhou, 310008, China.
Article Synopsis
- The study investigates the clinical usefulness of specific lung cancer-related autoantibodies in diagnosing non-small-cell lung cancer (NSCLC) and compares them with traditional cancer markers.
- The results showed that levels of the autoantibodies (CAGE, GBU4-5, MAGEA1, P53, PGP9.5, SOX2) were significantly higher in lung cancer patients than in other groups, indicating their potential as effective diagnostic tools (p < 0.01).
- The combined detection of these autoantibodies outperformed traditional markers like CEA, NSE, and CYFRA21-1, especially for adenocarcinoma and squamous cell carcinoma, suggesting a promising avenue for
Enhanced Lung Cancer Detection Using a Combined Ratio of Antigen-Autoantibody Immune Complexes against CYFRA 21-1 and p53.
Cancers (Basel)
July 2024
Department of Laboratory Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea.
Article Synopsis
- The study explores the use of autoantibodies as potential early biomarkers for lung cancer (LC), focusing on a new test called the 9G test Cancer/Lung, which measures antigen-autoantibody immune complexes.
- Analysis of 100 LC patients and 119 healthy controls revealed significantly higher levels of these immune complexes in LC patients, indicating a strong correlation with lung cancer diagnosis, particularly in early stages.
- The LC index, calculated from these immune complex ratios, showed superior diagnostic performance with 81% sensitivity and 95% specificity, highlighting its potential as a more effective diagnostic tool compared to traditional markers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!